{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:57:45Z","timestamp":1781323065732,"version":"3.54.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Intestinal mucosal healing is a key indicator for evaluating therapeutic efficacy and predicting long-term prognosis in ulcerative colitis (UC). Short-chain fatty acids (SCFAs) play an important role in maintaining intestinal homeostasis and promoting mucosal repair; however, their quantitative association with UC mucosal healing has not been fully elucidated. This study aimed to investigate the association between SCFA levels and endoscopic mucosal healing in UC patients and evaluate their clinical value as predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study enrolled 154 UC patients from January 2024 to March 2025, who were divided into a mucosal healing group (n\u2009=\u200968) and a non-healing group (n\u2009=\u200986) according to Mayo endoscopic scores, with an additional 50 healthy controls. Endoscopic evaluations were independently scored by two experienced gastroenterologists with substantial inter-rater reliability (\u03ba\u2009=\u20090.82). Gas chromatography-mass spectrometry was used to detect fecal SCFA concentrations, and real-time quantitative PCR (PCR stands for Polymerase Chain Reaction, a core molecular biology technique that allows for the rapid and specific amplification of specific DNA or RNA fragments in vitro) was employed to detect the expression levels of SCFA transporter protein SLC16A1 and metabolic enzyme genes in mucosal tissues. The association between SCFA levels and mucosal healing indicators was analyzed using multiple logistic regression adjusted for age, gender, disease duration, disease extent, and current medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The total fecal SCFA concentration in UC patients was significantly lower than that in healthy controls (P\u2009&amp;lt;\u2009.001). The butyrate concentration in the mucosal healing group was significantly higher than that in the non-healing group ([16.8\u2009\u00b1\u20097.3] vs [10.2\u2009\u00b1\u20094.6] mmol\/kg, P\u2009&amp;lt;\u2009.001). The SLC16A1 mRNA expression level in the mucosal healing group was 2.3-fold higher than that in the non-healing group, while ACSM3 and ACADS expression levels were elevated by 1.8-fold and 1.6-fold, respectively (all P\u2009&amp;lt;\u2009.001). Fecal butyrate concentration showed a significant negative correlation with Mayo endoscopic score (r\u2009=\u2009-0.647, P\u2009&amp;lt;\u2009.001). Multiple regression analysis revealed that fecal butyrate concentration was an independent predictor of mucosal healing (OR\u2009=\u20091.18, 95% CI: 1.09-1.28, P\u2009&amp;lt;\u2009.001). Receiver operating characteristic analysis demonstrated that butyrate had an area under the curve (AUC) of 0.847 for predicting mucosal healing, with a sensitivity of 76.5% and specificity of 81.4%. A combined model incorporating butyrate, C-reactive protein, and corticosteroid use achieved superior diagnostic performance (AUC\u2009=\u20090.896). The associations remained consistent across different disease extents and medication subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fecal SCFA levels in UC patients, particularly butyrate concentration, are closely associated with the degree of intestinal mucosal healing. Fecal butyrate concentration can serve as a non-invasive biomarker for assessing mucosal healing status in UC patients, providing objective evidence for individualized therapeutic strategy development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag106","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:20:19Z","timestamp":1779794419000},"source":"Crossref","is-referenced-by-count":0,"title":["Association analysis of short-chain fatty acid levels and intestinal mucosal healing in ulcerative colitis patients"],"prefix":"10.1093","author":[{"given":"Ben-Qiu","family":"He","sequence":"first","affiliation":[{"name":"Proctology, First Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine , Guiyang, Guizhou 550002,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7148-6247","authenticated-orcid":false,"given":"Xiang-Quan","family":"Lai","sequence":"additional","affiliation":[{"name":"Proctology, First Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine , Guiyang, Guizhou 550002,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"Proctology, Guizhou University of Traditional Chinese Medicine , Guiyang, Guizhou 550001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Proctology, Guizhou University of Traditional Chinese Medicine , Guiyang, Guizhou 550001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"2026061223443399700_izag106-B1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"2026061223443399700_izag106-B2","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026061223443399700_izag106-B3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2026061223443399700_izag106-B4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1751-2980.12849","article-title":"Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment","volume":"21","author":"Guo","year":"2020","journal-title":"J Dig Dis"},{"key":"2026061223443399700_izag106-B5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41598-021-81628-3","article-title":"Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study","volume":"11","author":"Zakerska-Banaszak","year":"2021","journal-title":"Sci Rep"},{"key":"2026061223443399700_izag106-B6","doi-asserted-by":"publisher","first-page":"1102420","DOI":"10.3389\/fmed.2022.1102420","article-title":"Disease clearance in ulcerative colitis: setting the therapeutic goals for future in the treatment of ulcerative colitis","volume":"9","author":"Ramos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026061223443399700_izag106-B7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut"},{"key":"2026061223443399700_izag106-B8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00535-023-02013-7","article-title":"Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis","volume":"58","author":"Parkes","year":"2023","journal-title":"J Gastroenterol"},{"key":"2026061223443399700_izag106-B9","doi-asserted-by":"publisher","first-page":"1429427","DOI":"10.3389\/fmed.2024.1429427","article-title":"Deep mucosal healing in ulcerative colitis: how deep is better?","volume":"11","author":"Jin","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026061223443399700_izag106-B10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ibd\/izz177","article-title":"Is endoscopic remission in ulcerative colitis still good enough?","volume":"25","author":"Bhattacharya","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026061223443399700_izag106-B11","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1038\/cti.2016.17","article-title":"Regulation of immune cell function by short-chain fatty acids","volume":"5","author":"Corr\u00eaa-Oliveira","year":"2016","journal-title":"Clin Transl Immunology"},{"key":"2026061223443399700_izag106-B12","doi-asserted-by":"publisher","first-page":"15949","DOI":"10.1038\/s41598-024-66574-0","article-title":"Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative colitis","volume":"14","author":"Deng","year":"2024","journal-title":"Sci Rep"},{"key":"2026061223443399700_izag106-B13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12964-023-01219-9","article-title":"Short-chain fatty acids in diseases","volume":"21","author":"Zhang","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2026061223443399700_izag106-B14","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/nu15102275","article-title":"Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review","volume":"15","author":"Recharla","year":"2023","journal-title":"Nutrients"},{"key":"2026061223443399700_izag106-B15","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.3390\/nu16234197","article-title":"Efficacy and safety of anthocyanin-rich extract in patients with ulcerative colitis: a randomized controlled trial","volume":"16","author":"Biedermann","year":"2024","journal-title":"Nutrients"},{"key":"2026061223443399700_izag106-B16","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat Commun"},{"key":"2026061223443399700_izag106-B17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ibd.21894","article-title":"Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway","volume":"18","author":"De Preter","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026061223443399700_izag106-B18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10753-019-01133-8","article-title":"The anti-inflammatory immune regulation induced by butyrate is impaired in inflamed intestinal mucosa from patients with ulcerative colitis","volume":"43","author":"Magnusson","year":"2020","journal-title":"Inflammation"},{"key":"2026061223443399700_izag106-B19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.immuni.2013.12.007","article-title":"Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis","volume":"40","author":"Singh","year":"2014","journal-title":"Immunity"},{"key":"2026061223443399700_izag106-B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12964-022-00869-5","article-title":"Regulatory role of short-chain fatty acids in inflammatory bowel disease","volume":"20","author":"Zhang","year":"2022","journal-title":"Cell Commun Signal"},{"key":"2026061223443399700_izag106-B21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"63","author":"Machiels","year":"2014","journal-title":"Gut"},{"key":"2026061223443399700_izag106-B22","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.3748\/wjg.v19.i22.3404","article-title":"Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India","volume":"19","author":"Kumari","year":"2013","journal-title":"WJG"},{"key":"2026061223443399700_izag106-B23","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1039\/d2fo01577c","article-title":"Strains producing different short-chain fatty acids alleviate DSS-induced ulcerative colitis by regulating intestinal microecology","volume":"13","author":"Yang","year":"2022","journal-title":"Food Funct"},{"key":"2026061223443399700_izag106-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18388\/abp.2018_2648","article-title":"Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs)","volume":"66","author":"Ratajczak","year":"2019","journal-title":"Acta Biochim Pol"},{"key":"2026061223443399700_izag106-B25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12876-022-02191-3","article-title":"Characterization of short-chain fatty acids in patients with ulcerative colitis: a meta-analysis","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2026061223443399700_izag106-B26","doi-asserted-by":"publisher","first-page":"E3941","DOI":"10.3390\/jcm9123941","article-title":"The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study","volume":"9","author":"Vernero","year":"2020","journal-title":"J Clin Med"},{"key":"2026061223443399700_izag106-B27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/19490976.2018.1526583","article-title":"Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels","volume":"10","author":"Valcheva","year":"2019","journal-title":"Gut Microbes"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag106\/68520237\/izag106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag106\/68520237\/izag106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:44:40Z","timestamp":1781322280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag106\/8707310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag106","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"article-number":"izag106"}}